title: Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
abstract: β-thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the deferasirox is proteinuria.
  
  
  
  This study aimed to investigate the safety of deferasirox on kidney function in diabetic and nondiabetic β-thalassemia major patients.
  
  
  
  In this cross-sectional study, 34 diabetic and 36 nondiabetic patients who take deferasirox (Exjade) 20 to 40 mg/kg/d were studied. Exclusion criteria included patient with renal failure, proteinuria, hepatitis B, hepatitis C, and the patients who refused to continue the study to the end. Subjects were divided into diabetic and nondiabetic groups. Spot urine protein/creatinine ratio, urinary analysis, alanine transaminase, aspartate transaminase, creatinine, fasting blood sugar, blood urea nitrogen, and serum ferritin were checked every 3 months. Patients were followed for a period of 1 year.
  
  
  
  In the ninth month after therapy there was a significant relationship in mean change of spot urine protein/creatinine ratio between diabetic and nondiabetic (P=0.011). Spot urine protein/creatinine ratio in diabetic and nondiabetic group was 0.19±0.18 and 0.1±0.05, respectively, which showed no significant relationship between the 2 groups at the end of study (P=0.162).
  
  
  
  The results of our study showed that consumption of deferasirox is safe, as there was no significant relationship between spot urine protein/creatinine ratio in diabetic and nondiabetic group. Deferasirox consumption is not associated with increased proteinuria in diabetic patients compared with nondiabetic group having only a transient proteinuria.
authors.affiliation: *Hematology Research Center †Department of Pediatrics, Hematology Research Center ‡Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Mehran
authors.initials: M
authors.lastname: Karimi
authors.forename: Abbas
authors.initials: A
authors.lastname: Avazpour
authors.forename: Sezaneh
authors.initials: S
authors.lastname: Haghpanah
authors.forename: Foroogh
authors.initials: F
authors.lastname: Toosi
authors.forename: Arash
authors.initials: A
authors.lastname: Badie
mesh_terms: D000293:Adolescent; D000328:Adult; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D003430:Cross-Sectional Studies; D000077588:Deferasirox; D000077543:Deferiprone; D003920:Diabetes Mellitus / Q000209:etiology* / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology; D008297:Male; D011507:Proteinuria / Q000139:chemically induced*; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use; D065227:Transfusion Reaction; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult; D017086:beta-Thalassemia / Q000150:complications* / Q000628:therapy / Q000652:urine
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003404:Creatinine; D000077588:Deferasirox